haha...all good hess. I know you tried your best to temper expectations after the abstract withdrawal and your email exchanges with a coordinator with adpd.
I can't say that I was not disappointed with no new data but the truth is I suppose is that more data from this extended trial is not what will propel us. Quite honestly, I'm not even so sure we would've seen a huge surge. If after positive results from our phase2a trial at CTAD and we were basically flat for weeks, what were the chances we would've seen a huge spike in SP with 15 month data? Starting our pivotal studies in the indications specified with positive results will be the only thing between existent and non-existent.
Market Data 
Markets 
AI
